Journal of the American College of Cardiology
-
J. Am. Coll. Cardiol. · Aug 2014
Review Meta AnalysisVery low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials.
Levels of atherogenic lipoproteins achieved with statin therapy are highly variable, but the consequence of this variability for cardiovascular disease risk is not well-documented. ⋯ The reductions of LDL-C, non-HDL-C, and apoB levels achieved with statin therapy displayed large interindividual variation. Among trial participants treated with high-dose statin therapy, >40% did not reach an LDL-C target <70 mg/dl. Patients who achieve very low LDL-C levels have a lower risk for major cardiovascular events than do those achieving moderately low levels.